Transcript Name of presentation
Wroclaw Research Centre EIT+ Ltd
Mirosław Miller
Wroclaw in nutshell
• Fourth largest city in Poland • Second highest budget • 1 million people • Lower Silesia region: 3 million • 11 universities • 140,000 students • 11,000 scientists • 5 billion EUR investment 2003-2010
Knowledge Based Economy Regionally – Wroclaw concept
1. Skilled people needed 2. Innovation supporting ecosystem incl. open infrastructure dedicated to innovation projects 3. Effective collaboration between academia – innovative industry 4. Local and central government support (incl. financial) 5. Trust between KBE actors: research - business 6. Financing available (from seed to venture) 7. Transfer of the best practices
Regional Strategy for Lower Silesia 2007 - 2013
The
EIT+
programme
Investing substantial portion of the EU-based structural and cohesion funds into: Making Lower Silesia the European Knowledge Region in the European Research Area (ERA) Making material conditions for strong partnership between Higher Education, Research and Innovative Business & Economy Making Lower Silesia a knowledge-based economy region
Academia Europaea in London and Wroclaw
Founded in 1988, with over 2000 members which includes leading experts from the physical sciences and technology, biological sciences and medicine, mathematics, the letters and humanities, social and cognitive sciences, economics and the law.
Wroclaw Research Centre EIT+
Shareholders
Wroclaw University of Technology University of Wroclaw Wroclaw Medical University Wroclaw University of Environmental and Life Sciences Wroclaw University of Economics Concept Lower Silesia Region
EIT+ Strategy
Maximum use of Structure Fond for the development of the Company and core competences The broad international presence (6 of the most innovative countries) Fast development of commercialisation and marketing department, acquisition of key customers The development of a portfolio of business projects with private partners from R&D and innovative economy sectors
Research areas: convergence technologies
Life Sciences Nanotechnology Climate and Energy ICT technologies
Key EIT+ projects financed from IE OP
NanoMat 31.1 m Euro Pracze Campus 140 m Euro BioMed 27.6 m Euro
City of Wrocław Climate EIT 300 T Euro ICT, 7 FP 2,5 m Euro IBM Fraunhofer EADS KGHM Accelerator spin-off 3 m Euro
Research and technology projects – role of EIT+
• Initiation of project (identification of real innovation needs) • Looking for business partner • Looking for research partner • Defining the financial model • Preparation of project application • Project management / coordination / administration • Key scientists responsible for the research area • Monitoring / reporting • Commercialization (IP management) •
After 2013: operation of the own infrastructure open for projets not for institution
Demand analysis
80% of R&D and co-development deals made by the top 10 pharma companies were with biotech and small pharma companies, with 7% attributed to partnerships with universities and academic institutions 1 . Market analysis 2. Research potential in Poland 3. Analysis of potential patrners
Market analysis
Areas of analysis Questions to analysis
The world-leading provider of premium Pharmaceutical & Healthcare and Retail industries.
global business information, delivering independent data, analysis and opinion in The most comprehensive database of private and public biomedical companies. We are searching pipeline, financial, competitive products, deals, mechanism of action, partnering, and patent information on biomedical companies, and products worldwide.
10 top pharma companies (Novartis, Elli Lilly etc), generic companies, emerging markets, mature markets, R&D strategies • • Market trends with particular emphasis on the need for research and biotechnology products Analysis of the activities of pharmaceutical companies and their demand for innovative R&D • Companies producing original drugs • Companies producing generic drugs
Market analysis – areas and questions
General Issues: Global biotechnology, Global venture capital insights and trends, Global pharmaceutical industry, New Approaches to Pharma R&D, Future Pharmaceutical Industry Trends, Licensing Strategy Update year in review Emerging Markets: Brazil, India, Russia, China, Top Pharma Players: Bayer AG, ,Boehringer Ingelheim GmbH, Merck & Co., Inc., Eli Lilly & Co., Pfizer Inc., J&J, Astra Zeneca, Hoffman-La Roche, GSK, Novartis, Sanofi-Aventis, Biologics:Merck KgA, Amgen, Teva Pharma 1.
Prescription pharmaceutical sales and growth rate performance ?
2 Financial performance?
3. Strategic insight key developments 4. SWOT analysis 5. Current corporate structure 6. M&A history 7.Product analysis 8. Launch/core/expiry analysis 9. Key products 1. Demographic trends 2. Political climate 3. Economic climate 4. Business environment 5. Healthcare expenditure 6. Healthcare system 7. Regulatory issues 8. Pricing and reimbursement 9. Generics market dynamics 10. Key generics players and pharmaceutical industry infrastructure overview
Commercialisation models
Key competence of EIT+ • Spin-off technology companies • Licensing • Project implementation in partnership with business (Academia to Business Forum)
„Innovation funnel”
Creating – investing in spin-off companies
EIT+ role in financing an early stage of R&D projects
Private Equity Stock Exchange
FORUM A2B
Seed Capital Business Angels
Spin off Accelerator GIZA POLAND VC
Venture Capital years
Pracze Campus today…
BLDG 9: BIOTECHNOLOGY LABORATORIES BLDG 7: BIOTECHNOLOGY AND NANOTECHNOLOGY LABORATORIES 17 BLDG1 B, C: MATERIALS CHARACTERISATION LABORATORIES BLDG 9 A: CHEMICAL SYNTHESIS AND NANOTECHNOLOGY LABORATORIES
EIT+ laboratories
• 34 research and technology laboratories of the total space over 24,000 m2: materials science, life sciences, medicine • 23 laboratories unique for Poland (GLP, GMP, BSL3 standards). • Multidisciplinary research centre of unique infrastructure for Wroclaw • 90 work places for people of high qualifications
Pracze Campus – basic concept
• open research infrastructure: project oriented (not institution oriented) • “critical mass” of the skilled people and R&D investors • “random meeting places” for: - creative and ambitious researchers and entrepreneurs - specialists of different expertise - local scientists and guest scientists visiting Pracze Campus - young and experienced scientists and industry partners • easily accessible for scientists and entrepreneurs • operated by the dedicated, market oriented company (EIT+) • financed by the projects realized in laboratories • additional expertise of importance: IP management, spin-offs establishing, marketing of research, patenting, project management, technology and capital funds
Wrocław „innovation pole” in Pracze
R&D investment area I R&D investment area II R&D investment area III
Pracze Campus today…
Pracze Campus in 2013
Pracze Campus in 2020
Wrocław Innovation Hub
EIT+ faces
EIT+ faces
Prof. dr. hab. Detlef Hommel
The
NanoMat
project coordinator
Prof. dr. hab. Jacek Otlewski
The
BioMed
project coordinator
EIT+ faces
Dr. Magdalena Ornatowska
Life Science Department
Dr.
Łukasz Nieradko
Nanotechnology Department
EIT+ faces
Dr.
Radosław Piesiewicz
ICT Department
Cezary Lejkowski
Climate and Energy Department
EIT+ and polish diaspora
Tomasz Mroczkowski
American University WASHINGTON
Oskar Zięta
ETH Zurich SWITZERLAN BREMEN ZURICH
Anna Topol
IBM Research NEW YORK
Prof. Andrzej Pawlak Janusz Liberkowski
USA
Karol Kozak
ETH Zurich SWITZERLAN
Dr Ami B. Friedman
MATIMOP OCS IZRAEL
Siew Hwa ONG, PhD
Director & Chief Scientist at Acumen Research Laboratories Pte Ltd, SINGAPUR
Dr Donald Wlodkowic
The BioMEMS Research Group NEW ZEALAND
Thank you
www.eitplus.pl